​​The Norwegian Medicines Agency urges all marketing authorization holders of OTC-medicinal products to:
  1. Harmonize existing package leaflets and labelling for OTC-medicinal products in accordance with the OTC substance report by submitting a notification. This is free of charges as long as the changes do not widen the already approved OTC-indication for the medicinal product. If the harmonization includes a broadening of the indication it will be charged as an OTC application.
  2. To compile separate package leaflets for OTC packs (OTC-PIL) in accordance with the OTC substance report for medicinal products in prescription group CF. OTC-PIL can be submitted for approval with the next variation for the medicinal product or as a separate notification, which will be free of charge. 

Publisert: 19.08.2016

​Fant du det du lette etter?